A T1a melanoma excision near critical structures with 5-mm margins may be adequate for a diminished risk of local recurrence compared to other excisions, according to recent findings.
Clinical Trials
REALITIVTY-047 Study Design Shows Mature Response Results in Melanoma
Jason Luke, MD, associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutics Center at the UPMC Hillman Cancer Center, discusses the unique design of the RELATIVITY-047 trial (NCT03470922) that demonstrated the efficacy of nivolumab (Opdivo) plus relatlimab (Opdualag) in patients with advanced melanoma.
Phase 2 KEYNOTE-695 Trial for Melanoma Treatment Did Not Reach Primary Endpoint
The phase 2 KEYNOTE-695 trial (NCT03132675), conducted by OncoSec Medical Incorporated, observed the efficacy of the combination of interleukin 12 (IL-12) encoding plasmid tavokinogene telseplasmid (TAVO-EP) plus IV pembrolizumab (Keytruda, Merck & Dohme LLC).
Pembrolizumab/Lenvatinib Combo Misses OS End Points in Select Advanced Melanoma and mCRC
The phase 3 LEAP-003 (NCT03820986) and LEAP-017 (NCT04776148) trials evaluating pembrolizumab (Keytruda) plus lenvatinib (Lenvima) did not meet their primary end points of overall survival (OS) in select patients with unresectable or metastatic melanoma and metastatic colorectal cancer (mCRC), respectively.